Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820989 · ClinicalTrials.gov registry record · Phase 1
Inflammation and the Host Response to Injury (In Healthy Volunteers)
A Phase 1 study of Immune System, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT00820989: Completed Phase 1 study of Immune System, sponsored by Rutgers, The State University of New Jersey.
NCT00820989 is a Phase 1 study of Immune System that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 116 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00820989, a Phase 1 study of Immune System, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
The body's immune response to injury or infection is very complex.Endotoxin is a man-made substance, which causes the body to "mimic" sickness (fever,chills, and achiness)for a few hours. This study is designed to determine whether certain proteins, genetics, or heart rate variability change affects the body's response to endotoxin.
Conditions Studied
Interventions
- BIOLOGICAL Endotoxin, Lipopolysaccharide, LPS
Study Locations (1)
New Jersey
- Rutgers-RWJMS - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2000-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
What the finished NCT00820989 record still lists
NCT00820989 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher).
The record links to 1 condition, with Immune System appearing as the primary indexed condition, and to 1 intervention - of which Endotoxin, Lipopolysaccharide, LPS is the first listed.
NCT00820989 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00820989 about?
NCT00820989 is a clinical study titled "Inflammation and the Host Response to Injury (In Healthy Volunteers)". The body's immune response to injury or infection is very complex.Endotoxin is a man-made substance, which causes the body to "mimic" sickness (fever,chills, and achiness)for a few hours. This study is designed to determine whether certain proteins, genetics, or heart rate variability change affects...
What is the current status of trial NCT00820989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2000-02. Estimated completion is 2011-02.
What conditions does trial NCT00820989 study?
This clinical trial studies the following conditions: Immune System.
What interventions are being tested in trial NCT00820989?
The interventions under investigation include: Endotoxin, Lipopolysaccharide, LPS (BIOLOGICAL).
Who is sponsoring clinical trial NCT00820989?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00820989 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00820989's enrollment target sits among peer trials
116 501st of 2000 higher than 1,497 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia